Capricor Therapeutics (CAPR) Total Non-Current Liabilities (2012 - 2026)

Capricor Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 268.52% year-over-year to $13.9 million in Q1 2026; TTM through Mar 2026 was $13.9 million, a 268.52% increase from a year earlier, with the FY2025 full-year figure at $14.3 million, up 258.68% from the prior year.
• Total Non-Current Liabilities fell to $13.9 million in Q1 2026 per CAPR's latest filing, from $14.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $26.0 million in Q1 2022 and bottomed at $194603.0 in Q2 2025.
• The 5-year median for Total Non-Current Liabilities is $8.1 million (2023), against an average of $10.0 million.
• Across the five-year window, Total Non-Current Liabilities surged 660.79% in 2022 and tumbled 95.6% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $14.7 million in 2022, then tumbled by 66.97% to $4.9 million in 2023, then decreased by 17.9% to $4.0 million in 2024, then jumped by 258.68% to $14.3 million in 2025, then declined by 2.63% to $13.9 million in 2026.
• Per Business Quant, the three latest CAPR Total Non-Current Liabilities figures stand at $13.9 million (Q1 2026), $14.3 million (Q4 2025), and $14.4 million (Q3 2025).